3 Wilson disease

Abstract Wilson disease is a recessively inherited disorder of copper transport. Clinical features are highly variable, with any combination of neurological, hepatic or psychiatric illness. The age of onset varies from 3 to 50 years of age. Diagnosis is challenging because no specific combination of clinical or biochemical features is necessarily definitive. The genetic defect is due to a variety of abnormalities in a copper-transporting membrane ATPase. Most of the more than 80 mutations are present at a low frequency, and mutations differ between ethnic groups. At least two mutations are sufficiently common to aid in rapid diagnosis, in European and Asian populations respectively. Molecular analysis can provide a definitive diagnosis for asymptomatic sibs. Treatment, using chelating agents or zinc, is most effective when started before permanent tissue damage occurs.

[1]  B. Portmann,et al.  Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease , 1992, Hepatology.

[2]  L. Farrer,et al.  Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Govindarajan,et al.  Hepatocellular carcinoma in a case of Wilson's disease. , 2008, Liver.

[4]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Vajro,et al.  Penicillamine-related neurologic syndrome in a child affected by Wilson disease with hepatic presentation. , 1997, Archives of neurology.

[6]  I. Sternlieb,et al.  Prevention of Wilson's disease in asymptomatic patients. , 1968, The New England journal of medicine.

[7]  D. Cox,et al.  The Wilson disease gene: spectrum of mutations and their consequences , 1995, Nature Genetics.

[8]  O. Mjølnerød,et al.  Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. , 1971, Lancet.

[9]  C. Datz,et al.  Detection of the His1069Gln Mutation in Wilson Disease by Rapid Polymerase Chain Reaction , 1997, Annals of Internal Medicine.

[10]  I. Sternlieb,et al.  The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. , 1987, New England Journal of Medicine.

[11]  T. Hoogenraad,et al.  Management of Wilson's disease with zinc sulphate Experience in a series of 27 patients , 1987, Journal of the Neurological Sciences.

[12]  Cox Dw Molecular advances in Wilson disease. , 1996 .

[13]  S. Virgiliis,et al.  Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations. , 1995, American journal of human genetics.

[14]  J. Jankovic,et al.  Neurologic presentation of Wilson disease without Kayser-Fleischer rings , 1996, Neurology.

[15]  Burton Combes,et al.  Low serum alkaline phosphatase activity in Wilson's disease , 1986, Hepatology.

[16]  I. Sternlieb Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. , 1968, Gastroenterology.

[17]  J. Rommens,et al.  The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene , 1993, Nature Genetics.

[18]  L. Deecke,et al.  Wilson's disease , 1993, Neurology.

[19]  R. Russell,et al.  Use of a stable copper isotope (65Cu) in the differential diagnosis of Wilson's disease. , 1995, Clinical science.

[20]  J. Walshe,et al.  DIAGNOSIS AND TREATMENT OF PRESYMPTOMATIC WILSON'S DISEASE , 1988, The Lancet.

[21]  R. Kliegman,et al.  Pigmented corneal rings in neonates with liver disease. , 1987, The Journal of pediatrics.

[22]  T. Gilliam,et al.  Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. , 1997, American journal of human genetics.

[23]  M. Czaja,et al.  Hepatocellular copper toxicity and its attenuation by zinc. , 1989, The Journal of clinical investigation.

[24]  J. Walshe TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDE , 1982, The Lancet.

[25]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[26]  J. Walshe,et al.  Chelation treatment of neurological Wilson's disease. , 1993, The Quarterly journal of medicine.

[27]  D W Cox,et al.  The toxic milk mouse is a murine model of Wilson disease. , 1996, Human molecular genetics.

[28]  G. Hill,et al.  Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens , 1987, Hepatology.

[29]  J. Morita,et al.  Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations. , 1992, Developmental Pharmacology and Therapeutics.

[30]  D. Cox,et al.  Haplotypes and mutations in Wilson disease. , 1995, American journal of human genetics.

[31]  A. Young,et al.  Initial therapy of patients with Wilson's disease with tetrathiomolybdate. , 1991, Archives of neurology.

[32]  D. Cox,et al.  The Application of DNA Markers to the Diagnosis of Presymptomatic Wilson Disease , 1989 .

[33]  T. Gilliam,et al.  Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. , 1997, The Biochemical journal.

[34]  P. Ryan,et al.  Penicillamine, its metabolism and therapeutic applications: A review , 1979, Biopharmaceutics & drug disposition.

[35]  S. Packman,et al.  Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase , 1993, Nature Genetics.

[36]  G. Brewer,et al.  Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. , 1997, The Journal of laboratory and clinical medicine.

[37]  J. Walshe Pregnancy in Wilson's disease. , 1977, The Quarterly journal of medicine.

[38]  G. Mieli-Vergani,et al.  Failure of simple biochemical indexes to reliably differentiate fulminant wilson's disease from other causes of fulminant liver failure , 1992, Hepatology.

[39]  P. Kuan Cardiac Wilson's disease. , 1987, Chest.

[40]  P. Hedera,et al.  Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy , 1996 .

[41]  C. Lui,et al.  Neurological improvement of Wilson's disease after liver transplantation. , 1997, Transplantation proceedings.

[42]  J. Rathbun,et al.  Neuropsychological aspects of Wilson's disease. , 1996, The International journal of neuroscience.

[43]  J. Walshe,et al.  Wilson's disease: the problem of delayed diagnosis. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[44]  T. Dening,et al.  Wilson's disease and epilepsy. , 1988, Brain : a journal of neurology.

[45]  S. Sherlock,et al.  Wilson's disease, presenting as chronic active hepatitis , 1978 .

[46]  A. Rötig,et al.  Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. , 1995, Gastroenterology.

[47]  I. Saatci,et al.  Cranial MR findings in Wilson's disease , 1997, Acta radiologica.

[48]  H. Hefter,et al.  Wilson disease: clinical presentation, treatment, and survival. , 1991, Annals of internal medicine.

[49]  H. Popper,et al.  Progress in Liver Diseases , 1962 .

[50]  P. Harper,et al.  REVERSIBLE PANCYTOPENIA SECONDARY TO TREATMENT WITH TETRATH10‐MOLYBDATE , 1986, British journal of haematology.

[51]  S. Nakada,et al.  Wilson's disease presenting as symptomatic urolithiasis: a case report and review of the literature. , 1994, The Journal of urology.

[52]  G. de las Heras,et al.  Wilson's disease treated with trientine during pregnancy. , 1995, Journal of pediatric gastroenterology and nutrition.

[53]  R. Calne,et al.  Reversal of severe neurological manifestations of Wilson's disease following orthotopic liver transplantation. , 1987, The Quarterly journal of medicine.

[54]  L. Cavalli-Sforza,et al.  Predictive testing for Wilson's disease using tightly linked and flanking DNA markers , 1991, Neurology.

[55]  B. Neuschwander‐Tetri,et al.  Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. , 1994, Gastroenterology.

[56]  S. Sherlock,et al.  IS WILSON'S DISEASE CAUSED BY A CONTROLLER GENE MUTATION RESULTING IN PERPETUATION OF THE FETAL MODE OF COPPER METABOLISM INTO CHILDHOOD? , 1981, The Lancet.

[57]  E. Cauza,et al.  Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. , 1997, Journal of hepatology.

[58]  L. Wetterberg Genetics of Neuropsychiatric Diseases , 1989 .

[59]  K. Hambidge,et al.  Treatment of Wilson's Disease with Triethylene Tetramine Hydrochloride (Trientine) , 1990, Journal of pediatric gastroenterology and nutrition.

[60]  J. Kaplan,et al.  N-terminal Domains of Human Copper-transporting Adenosine Triphosphatases (the Wilson’s and Menkes Disease Proteins) Bind Copper Selectively in Vivo and in Vitro with Stoichiometry of One Copper Per Metal-binding Repeat* , 1997, The Journal of Biological Chemistry.

[61]  I. Sternlieb,et al.  Pregnancy in penicillamine-treated patients with Wilson's disease. , 1975, The New England journal of medicine.

[62]  A. Aisen,et al.  Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. , 1994, Archives of neurology.

[63]  J M Walshe,et al.  Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. , 1989, The Quarterly journal of medicine.

[64]  Jingshi Wu,et al.  The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene , 1994, Nature Genetics.

[65]  J. Peppercorn,et al.  The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene , 1993, Nature Genetics.

[66]  E. Dickson,et al.  Diagnosis of Wilson's disease presenting as fulminant hepatic failure. , 1983, Gastroenterology.

[67]  G. Corazza,et al.  Zinc therapy in Wilson's disease: observations in five patients. , 1990, The American journal of gastroenterology.

[68]  I. Sternlieb,et al.  Prognosis of Wilsonian chronic active hepatitis. , 1991, Gastroenterology.

[69]  D. Pessayre,et al.  Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. , 1997, Gastroenterology.

[70]  I. Koyama,et al.  Low serum alkaline phosphatase activity associated with severe Wilson's disease. Is the breakdown of alkaline phosphatase molecules caused by reactive oxygen species? , 1995, Clinica chimica acta; international journal of clinical chemistry.

[71]  R. Klausner,et al.  Biochemical Characterization of the Wilson Disease Protein and Functional Expression in the Yeast Saccharomyces cerevisiae * , 1997, The Journal of Biological Chemistry.

[72]  T. Nakajima,et al.  Haplotype and mutation analysis in Japanese patients with Wilson disease. , 1997, American journal of human genetics.

[73]  K. Schärer,et al.  Proteinuria and other renal functions in Wilson’s disease , 1997, Pediatric Nephrology.

[74]  J. Walshe The management of pregnancy in Wilson's disease treated with trientine. , 1986, The Quarterly journal of medicine.

[75]  A. Herneth,et al.  Wilson's disease in patients presenting with liver disease: a diagnostic challenge. , 1997, Gastroenterology.

[76]  J. Sarles,et al.  Successful medical treatment of severely decompensated Wilson disease. , 1996, The Journal of pediatrics.

[77]  R. Sokol,et al.  Abnormal hepatic mitochondrial respiration and cytochrome C oxidase activity in rats with long-term copper overload. , 1993, Gastroenterology.

[78]  A. Algra,et al.  Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. , 1996, Radiology.

[79]  C. Lang,et al.  Fatal deterioration of Wilson's disease after institution of oral zinc therapy. , 1993, Archives of neurology.

[80]  W. Stremmel,et al.  Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. , 1994, Journal of hepatology.

[81]  J. Juyn,et al.  H714Q mutation in Wilson disease is associated with late, neurological presentation. , 1995, Journal of medical genetics.

[82]  G. Brewer,et al.  Treatment of Wilson's disease with zinc. , 1999, The Journal of laboratory and clinical medicine.

[83]  I. Sternlieb,et al.  Liver transplantation for Wilson's disease: Indications and outcome , 1994, Hepatology.

[84]  D. Cox,et al.  Expression, Purification, and Metal Binding Properties of the N-terminal Domain from the Wilson Disease Putative Copper-transporting ATPase (ATP7B)* , 1997, The Journal of Biological Chemistry.

[85]  Caballero Et,et al.  [Wilson's disease]. , 1965 .

[86]  B. Esmaeli,et al.  Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease. , 1996, Cornea.

[87]  I. Sternlieb Fraternal concordance of types of abnormal hepatocellular mitochondria in Wilson's disease , 1992, Hepatology.

[88]  J. Walshe,et al.  Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. , 1995, Archives of neurology.